QMS Software Validation: FDA Part 11 and GxP eQMS Guide

Regulatory Context for QMS Software Validation

QMS software validation sits at the intersection of computerized system validation, electronic records, quality system records, and company procedures. The exact obligation depends on intended use.

For pharmaceutical manufacturers, 21 CFR Part 211 requires written procedures and records across GMP operations. If the eQMS controls deviations, CAPA, change control, training, document control, complaints, supplier qualification, validation records, or batch-release support, those records may support GMP decisions. The software does not become regulated because it is called an eQMS. It becomes relevant because the company relies on it for regulated work.

For medical device manufacturers, 21 CFR Part 820 now reflects FDA's QMSR framework. FDA states that QMSR became effective on February 2, 2026 and incorporates ISO 13485:2016 by reference, with additional FDA requirements in Part 820. A device eQMS may control design records, risk files, supplier controls, complaints, CAPA, management review evidence, quality audit evidence, and eSTAR submission support.

For electronic records and signatures, 21 CFR Part 11 may apply when records required by predicate rules are maintained electronically in place of paper, relied on electronically to perform regulated activities, submitted electronically to FDA, or signed electronically as the equivalent of handwritten signatures. FDA's Part 11 Scope and Application guidance is important because it keeps the analysis focused on record use rather than vendor slogans.

FDA's computer software assurance guidance for production and quality management system software also matters. It emphasizes using a risk-based approach to establish confidence that software is fit for its intended use. For QMS software, that means validation evidence should scale with patient safety, product quality, and data integrity risk.

What Does QMS Software Validation Prove?

Validation should prove that the system can perform its intended regulated use.

Examples:

• SOP approval workflow routes documents correctly.
• Electronic signatures capture required meaning and identity.
• Audit trails record changes to regulated records.
• Obsolete documents are controlled.
• CAPA records preserve approvals and history.
• Training assignments are triggered by effective documents.
• Records can be retrieved during inspection.

For a broader CSV foundation, see the computerized system validation guide.

The validation should not try to prove every theoretical feature in the platform. It should prove the configured workflows the company actually relies on. A vendor may support complaint handling, supplier quality, training, CAPA, document control, audits, and change control. If your implementation only uses document control and training at go-live, the initial validation package should focus there, while defining how future modules will be assessed before use.

Good validation evidence answers five questions:

1. What regulated activity does the system support?
2. Which records are authoritative in the system?
3. Which controls protect those records?
4. Which configured workflows were tested?
5. How will the validated state be maintained after go-live?

If those questions are not answered, a thick validation binder can still be weak.

Risk-Based Validation Approach

Validation should be sufficient, not performative.

Risk-based validation does not mean informal validation. It means the testing rationale is documented and proportionate. A low-risk dashboard filter may need limited verification. An electronic signature approving a CAPA closure needs more attention because the signature has approval meaning and may be relied on in an inspection.

A practical risk model should consider:

• Product quality impact
• Patient or user safety impact
• Data integrity impact
• Record retention and retrieval impact
• Regulatory submission impact
• Inspection or audit reliance
• Frequency of use
• Complexity of configuration
• Degree of customization
• Integration and data-transfer risk

Use that risk model to decide how deeply to test each workflow. For example, a CAPA workflow may require tests for intake, classification, root cause, action approval, effectiveness check, closure, extensions, permissions, audit trail, and export. A read-only reference library may only require tests for access, document retrieval, and version display.

Validation Deliverables for an eQMS

The validation package should be readable by quality, IT, regulatory, and an inspector. It should not depend on tribal knowledge or vendor-only terminology.

Typical deliverables include:

For small teams, these documents can be lean. A startup does not need an enterprise-style validation package for a narrow implementation. But the core logic still needs to be present: intended use, risk, requirements, testing, procedures, training, and approval.

Part 11 Considerations

FDA's Part 11 guidance explains that Part 11 applies when records required by predicate rules are maintained electronically in place of paper, and to electronic signatures intended as the equivalent of handwritten signatures.

For QMS software, evaluate:

• System validation
• Secure access controls
• Audit trails
• Electronic signature manifestations
• Signature-to-record linking
• Record retention and retrieval
• Authority checks
• User training
• Copies of records for inspection

The company should document which QMS records are Part 11 records and why.

Part 11 testing should be scenario-based. Do not only test that an audit trail exists. Test whether the audit trail captures meaningful changes to a regulated record, whether ordinary users can alter or disable it, whether timestamps and user identities are preserved, and whether the audit trail can be reviewed in a human-readable way.

For electronic signatures, test the full signature behavior:

• Unique user signs using controlled credentials
• Signature includes printed name, date and time, and meaning
• Signature is linked to the record
• Record changes after signing are controlled
• Signature manifestation appears on viewed or exported records where needed
• Password and user ID controls follow company procedure

For record copies, test the export the company would actually provide during inspection. A PDF that omits status, version, approval meaning, or attachments may be inadequate even if the on-screen record looked complete.

SaaS eQMS Validation and Release Management

Most modern QMS platforms are SaaS systems. SaaS does not remove validation responsibility. It changes the operating model.

The vendor typically controls infrastructure, baseline platform development, hosting, security controls, and periodic releases. The regulated company controls intended use, configuration, procedures, training, access decisions, workflow ownership, data quality, and assessment of vendor changes against its validated use.

Before go-live, clarify:

• How often the vendor releases updates
• How release notes are communicated
• Whether releases can be deferred
• Which changes affect validated workflows
• How sandbox testing works
• How customer configuration is documented
• What validation documentation the vendor provides
• How incidents, outages, and data restoration are handled

After go-live, the company should have a release impact assessment process. Not every vendor release requires full regression testing. But every release that could affect regulated workflows, signatures, audit trails, permissions, records, reports, integrations, or exports should be reviewed and documented.

This is one of the most common weak points in eQMS validation. Teams validate at implementation, then fail to maintain the validated state as releases, configuration changes, new modules, new user roles, integrations, and business processes evolve.

Workflow Tests That Matter Most

The exact tests depend on the implementation, but these scenarios are common:

Each test should have expected results. "User can approve document" is weaker than "QA Approver can apply an approval signature with meaning 'approval', the document status changes to approved, the effective date remains pending until release criteria are met, and the audit trail records the action."

Common Validation Mistakes

Other common issues include validating too late, copying a vendor template without adapting it, failing to test negative permissions, and not documenting why some features are out of scope. A clean validation package should make scope boundaries visible. If supplier management is not live yet, say so. If electronic signatures are only used for document approval and CAPA closure, say so. If a dashboard is informational and not used for release decisions, say so.

The opposite problem is over-validation. Testing every screen and every low-risk report creates noise and slows down implementation without improving confidence. Inspectors and auditors are not impressed by volume if the important workflows are weak.

How Assyro Supports Validation Readiness

Assyro can help teams connect QMS validation to regulated evidence readiness. Regulatory Gap Analysis, QMS document control software, and audit trail requirements content can support the validation narrative: the system must preserve trustworthy records that can support quality decisions, inspections, and submissions.

The regulatory value is strongest when validation evidence links to downstream use. If a CAPA record may support a response to FDA, the validation should show the CAPA workflow preserves the record history and approval meaning. If a change control may drive a CMC supplement, the validation should show the eQMS preserves impact assessment, approvals, attachments, and traceability to implementation evidence. If a document control workflow supports submission source documents, the validation should show version control, signatures, retrieval, and export.

Validation readiness is part of the larger quality-to-regulatory operating model. The goal is not just to pass an eQMS validation exercise. The goal is to make sure the records created in the eQMS can be trusted when they are used in inspections, submissions, regulatory responses, management review, and product-quality decisions.

References

This guide reflects FDA Part 11 and regulated-record information current as of May 2026. Confirm intended use, predicate rules, and company validation procedures before implementation.